SCHEMBL17729941

SCHEMBL17729941

O=C(NCCCCBr)C1c2ccccc2-c2ccccc21

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.54
DRD4 P21917 3/20 0.54
DRD3 P35462 3/20 0.54
HDAC3 O15379 1/20 0.53
HDAC4 P56524 1/20 0.53
HDAC7 Q8WUI4 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
HDAC9 Q9UKV0 1/20 0.53
HDAC5 Q9UQL6 1/20 0.53
NCOR2 Q9Y618 1/20 0.53
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
MAPT P10636 1/20 0.50
ALDH1A1 P00352 1/20 0.48
ALOX15 P16050 1/20 0.48
NPC1 O15118 1/20 0.45
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6649148 0.79 HDAC3 (0.58) DRD2DRD4DRD3HDAC3HDAC4
SCHEMBL16492277 0.79 HDAC3 (0.58) DRD2DRD4DRD3HDAC3HDAC4
SCHEMBL15809775 0.76 KMT2A (0.73) KMT2A
SCHEMBL5863481 0.75 KMT2A (0.51) DRD2DRD4DRD3HDAC3HDAC4
SCHEMBL11571372 0.74 TAAR1 (0.48) DRD2DRD4DRD3HDAC3HDAC4
SCHEMBL9398200 0.73 HDAC3 (0.59) DRD2DRD4DRD3HDAC3HDAC4
SCHEMBL6649484 0.72 LMNA (0.69) DRD2DRD4DRD3HDAC3HDAC4
SCHEMBL4597996 0.71 HDAC3 (0.56) DRD2DRD4DRD3HDAC3HDAC4
SCHEMBL18025027 0.71 KMT2A (0.39) HDAC3HDAC4HDAC7HDAC8HDAC6
SCHEMBL7338781 0.71 KMT2A (0.70) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10934251-B2 Process for the preparation of lomitapide HETERO RESEARCH FOUNDATION (IN) 2021-03-02 US claimed
US-20200190018-A1 Process For The Preparation of Lomitapide HETERO RESEARCH FOUNDATION (IN) 2020-06-18 US claimed
US-10023526-B2 Process for the preparation of lomitapide HETERO RESEARCH FOUNDATION 2018-07-17 US claimed
US-20180105487-A1 PROCESS FOR THE PREPARATION OF LOMITAPIDE HETERO RESEARCH FOUNDATION (IN) 2018-04-19 US claimed
EP-3215490-A1 PROCESS FOR THE PREPARATION OF LOMITAPIDE Hetero Research Foundation (IN) 2017-09-13 EP claimed
WO-2016071849-A1 PROCESS FOR THE PREPARATION OF LOMITAPIDE HETERO RESEARCH FOUNDATION (IN) 2016-05-12 WO claimed
US-10934251-B2 Process for the preparation of lomitapide HETERO RESEARCH FOUNDATION (IN) 2021-03-02 US disclosed
US-20200190018-A1 Process For The Preparation of Lomitapide HETERO RESEARCH FOUNDATION (IN) 2020-06-18 US disclosed
US-20180291773-A1 PROCESS FOR THE PREPARATION OF LOMITAPIDE HETERO RESEARCH FOUNDATION (IN) 2018-10-11 US disclosed
US-10023526-B2 Process for the preparation of lomitapide HETERO RESEARCH FOUNDATION 2018-07-17 US disclosed
US-20180105487-A1 PROCESS FOR THE PREPARATION OF LOMITAPIDE HETERO RESEARCH FOUNDATION (IN) 2018-04-19 US disclosed
EP-3215490-A1 PROCESS FOR THE PREPARATION OF LOMITAPIDE Hetero Research Foundation (IN) 2017-09-13 EP disclosed
WO-2016071849-A1 PROCESS FOR THE PREPARATION OF LOMITAPIDE HETERO RESEARCH FOUNDATION (IN) 2016-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180105487-A1 PROCESS FOR THE PREPARATION OF LOMITAPIDE LIPA, LPAR4, CETP DRD2 2739/4885DRD4 2295/4885DRD3 2391/4885
US-10023526-B2 Process for the preparation of lomitapide LIPA, LPAR4, CETP DRD2 2739/4885DRD4 2295/4885DRD3 2391/4885
US-20200190018-A1 Process For The Preparation of Lomitapide LIPA, LPAR4, CETP DRD2 2739/4885DRD4 2295/4885DRD3 2391/4885
US-10934251-B2 Process for the preparation of lomitapide LIPA, LPAR4, CETP DRD2 2739/4885DRD4 2295/4885DRD3 2391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.